所有患者在输注 CART-123 前都接受了氟达拉滨(fludarabine)和环磷酰胺(cyclophosphamide)淋巴细胞清楚的标准调理治疗。 在评估反应的六名患者中 ...
Initial Clinical Data from Phase 1 Autoimmunity Study of FT819 1XX CAR T-cell Product Candidate to be Presented in 4Q24; ...
FATE reports a narrower-than-expected loss on higher revenues for the third quarter of 2024. The company's innovative ...
LOUISVILLE, Ky. -- A CD70-targeted CAR T-cell therapy for advanced kidney cancer continued to show durable activity in ...
A new research paper titled "ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells" has been published in Oncotarget.
BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.
The FDA has approved obecabtagene autoleucel (Aucatzyl) to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Hematopoietic stem cell transplant (HSCT) after first complete remission appears more effective than non-HSCT consolidation in older patients with AML.
The FDA approved obecabtagene autoleucel for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.
Nkarta is working on engineered NK cell therapies for autoimmune diseases and cancer. Click here to find out why I maintain a ...
Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes #469 oral presentation Session: 626.